Meta-analysis ofGinkgo bilobaPreparation for the Treatment of Alzheimer's Disease

Objective The objective of this study was to investigate the efficacy and safety ofGinkgo bilobapreparation for the treatment of Alzheimer disease (AD). Methods Both English (PubMed, Embase, Cochrane Library databases, and the Cochrane Controlled Trials Register) and Chinese (WanFang, Chinese Biomedical, CNKI, and VIP databases) databases were systematically and independently searched by 2 authors from their inception until July 3, 2019. All relevant studies included AD patients who were treated withGinkgo biloba. The efficacy and safety of the medicine were used as the main measurement index. Results Seven studies (N = 939) were identified and analyzed. When compared with placebo,Ginkgo bilobashowed exact validity in cognitive function and global clinical assessment (cognitive function section: risk ratio = 1.98, 95% confidence interval = 1.52-2.59,Z= 5.12,P< 0.001; according to Clinical Global Impression Change: odds ratio = 3.119, 95% confidence interval = 2.206-4.410,Z= 6.44,P< 0.001). Adverse events were mild. Conclusions Ginkgo bilobapreparation has reliable efficacy of cognitive function and global clinical assessment and safety in the treatment of AD.